ANVISA approves Vexim’s SpineJack implants in Brazil

5th June 2017

435

Vexim’s SpineJack system

Vexim has received regulatory approval from ANVISA (Agência Nacional de Vigilância Sanitária), Brazil’s National Health Surveillance Agency, in order to commercialise the company’s SpineJack in the country.

According to a company release, the approval will open a new opportunity for Vexim in an important international market with untapped potential. VEXIM estimates that Brazil alone today represents a €15 million market in the vertebral compression fractures field.

“The company is expecting to initiate export to Brazil in the coming months, after the conclusion of the product’s evaluation process and of distribution partnerships”, says Vincent Gardès, chief executive officer of Vexim.